Although the association between antidepressant drug use and risk of cancer has received considerable attention in the past years, no work has been done specifically on prostate cancer. We carried out a population-based case -control study to assess the risk of prostate cancer in association with exposure to tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). 7767 prostate cancer cases diagnosed between 1981 and 2000 were accrued through the Saskatchewan Cancer Agency. Saskatchewan Health identified a total of 31 068 male controls who were matched on age and calendar time. Data on exposure to TCAs and SSRIs were compiled from the Saskatchewan outpatient prescription drug database, and covered a period upto 24 years. A positive significant association was found between TCA use and risk of prostate cancer, when exposure took place 2-5 years before diagnosis, with rate ratios of 1.31, 1.58, and 2.42 at the low, medium and high average daily dose levels, respectively. Exposure to SSRIs was not found to be significantly associated with the risk of prostate cancer. TCA use 2-5 years in the past was associated with a small dose-dependent increase in the risk of prostate cancer. Nevertheless, detection bias could have contributed to the observed association.
Introduction
Experimental studies have raised concern that antidepressants may cause cancer in humans. Specifically, tricyclic antidepressants (TCAs), which were the most commonly used antidepressants until the mid-1990s, were found to promote tumor growth in a number of rodent models of colon cancer. 1 It has been suggested that some TCAs may increase cancer risk because their chemical structure is similar to a tamoxifen derivative that increases DNA synthesis in malignant cells and stimulates tumor growth in rodents. 2 Conversely, other studies indicated that some antidepressants may protect against cancer. For instance, the TCAs imipramine-and clomipramine-induced apoptosis in human acute leukemia cells in one experiment 3 and inhibited the development of lung metastases in another. 4 Whereas the relationship between antidepressant use and risk of breast and ovarian cancer was the subject of few observational studies, [5] [6] [7] [8] [9] [10] the association with prostate cancer was not, to our knowledge, specifically investigated. Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer death among men in the United States 11 and Canada. 12 Antidepressants are among the most widely used medications and are commonly prescribed for psychiatric and medical conditions such as depression, anxiety disorders and chronic pain. It is therefore important to clarify the relationship between prostate cancer and antidepressant use.
In 2002, our group carried out a population-based nested case -control study, using data from the Saskatchewan Cancer Agency registry and Saskatchewan Health's health insurance registry and drug plan, to investigate the relationship between antidepressant use and the risk of each of 17 types of cancer. 13, 14 This paper presents the results on the association between antidepressant use and risk of prostate cancer. Our main aim was to measure the effect of using TCAs and selective serotonin reuptake inhibitors (SSRIs) on the risk of developing prostate cancer. In addition, we measured the effect of duration of use and assessed latency and dose -response effects.
Patients and methods
The details of the original study have been published elsewhere. 13, 14 Briefly, we carried out a population-based nested case -control study using data compiled from the databases of the Saskatchewan Cancer Agency and Saskatchewan Health, specifically the cancer registry and the outpatient prescriptions drug and health insurance registration databases. The source population was the dynamic cohort defined by registration with Saskatchewan Health from 1 January 1981 to 31 December 2000 and eligible for prescription drug benefits. It included all people aged between 5 and 82.5 years, living in Saskatchewan and registered with Saskatchewan Health at least 5 years earlier and eligible for outpatient prescription drug benefits, and with no prior history of cancer (except for non-melanoma skin cancer). Study procedures were approved by the Research Ethics Committee of the Lady Davis Institute for Medical Research, Montreal, Canada.
The Saskatchewan Cancer Agency registry identified the persons diagnosed with any of the 17 cancer types, considered in the original study, between 1 January 1981 and 31 December 2000. The date of diagnosis for each cancer case, as recorded in the cancer registry, was defined as the index date. Using incidence density sampling, each case was matched to at least four controls. Controls had to be alive of cancer in the month that the case was diagnosed, had to fall within the same age category as the case at the time of diagnosis (intervals of 2.5 years), and had to be of the same sex as the case. The selected controls were then used as controls for all the cases of the 17 different anatomical sites. The date of diagnosis for the case was assigned to each of the controls as their index date. Controls had to have no history of cancer at index date. The present analyses were restricted to men in the source population with primary prostate carcinoma (ICD-O code 61) and their controls (who were randomly selected from the available controls).
Data on exposure to TCAs and SSRIs, for both cases and controls, were compiled from the outpatient prescription drug database for the period between 1 January 1976 or the first ever coverage initiation date (whichever was later) and the index date. For each antidepressant prescription, the following data were available: the dispensing date, the active ingredient, the quantity dispensed, the dosage form and the strength (for example, mg/tablet).
Statistical analyses
Two different approaches were used to assess the association between use of antidepressants (as measured by the prescriptions to these drugs) and risk of prostate cancer. In the first set of analyses, we used two exposure indices that characterized the pattern of TCA and SSRI use throughout the entire history of the study subjects: (1) ever/never use and (2) cumulative dosage exposure. These analyses were stratified by duration of the history of enrollment with Saskatchewan Health. Thus, for the TCA analyses, subjects were categorized into four mutually exclusive groups; those having up to 5, 10, 15 and 20 years of history, respectively. For the analyses pertaining to the SSRIs, all subjects having a history of up to 10 years before the index date were combined together, since the first SSRI was listed in the Saskatchewan Formulary in 1989. Exposure to antidepressants in the year immediately preceding the index date was excluded from all analyses to avoid protopathic bias (the early symptoms of an undiagnosed prostate cancer could have been the reason for the use of antidepressants). In the 'ever/never exposure' index a subject was categorized as exposed if he filled at least one prescription of the drug group under study. The 'cumulative dosage exposure' index was defined as the total quantity, in moles (gram molecular weights), of each drug dispensed and was calculated by multiplying the drug's molecular weight, as given in the Merck Index, by the total number of drug units dispensed. 15 Cumulative exposure was used as a continuous and as a categorical variable (cutoff points were selected based on their distributions to increase the power by ensuring that the different categories have enough subjects). In these analyses, the reference group was defined as those who were not exposed to the medication of interest.
To study the effect of timing of exposure to antidepressants on the risk of prostate cancer, we divided the drug history preceding the index date into four successive periods: 2-5, 6-10, 11-15 and 16-20 years. Exposure within each period was characterized in two ways: (1) as an average daily dose, and (2) as duration of use. The average daily dose index was calculated as the total number of moles of each drug group dispensed during each period divided by the number of days in that period to give the average number of moles of TCAs or SSRI dispensed per day. For each time period, the average daily dose was represented by continuous and by categorical variables: low, medium and high. To estimate the duration of drug use, each time period was divided into 3-month intervals (91 days) and then the number of intervals during which at least one prescription of the index drug was dispensed was counted (for example, drug use during 11 of 20 intervals represented a duration of 55% for the 20 intervals). Similarly, within each time period duration of use was represented by continuous variables, as well as categorical variables: unexposed, short, medium and long. In these analyses, the reference group comprised subjects who did not fill any prescription of the medication of interest during the specified period. If the drug exposure for a specific period was missing or was incomplete due to the coverage initiation date (that is, the patient entered the study during this period), the subject was assigned to a separate exposure category designated as 'other'. 16 Conditional logistic regression was carried out to calculate matched odds ratios, with 95% confidence intervals, to estimate rate ratios (RRs). In addition, for exposures measured on a continuous scale, we tested for the linear trend by examining the significance of the coefficients with a w 2 test (P-trend). In all models, we controlled for the potentially confounding effects of other drugs that may be related to the occurrence of the prostate cancer (sedatives and hypnotics, lithium, corticosteroids, disease-modifying antirheumatic drugs, Antidepressants and risk of prostate cancer HM Tamim et al systemic cardiovascular disease drugs, calcium channel blockers and non-steroidal anti-inflammatory drugs). Moreover, we adjusted for the number of prescriptions in the 5-year period before the index date, which was considered as a proxy to the frequency of receiving health services. When examining the effect of timing of exposure to antidepressants, we also controlled for the exposure to antidepressants during the other three time periods. We assumed that successive time periods of exposure can be viewed as separate determinants of the outcome that can be mutually confounded, thus requiring separate representation in the same statistical model. 17 All data management and analyses were carried out using SAS version 8.0. 18 
Results
During the 20-year study period (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) , there were 7767 cases of prostate cancer identified in the province of Saskatchewan, who were matched to 31 068 controls ( Table 1 ). The median age at diagnosis for cases was 71.4 years (25th percentile ¼ 66.3, and 75th percentile ¼ 75.8). 
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The median drug exposure history available was about 16.8 years for both cases and controls. Among cases, 27.6 and 7.3% had at least one prescription of TCAs and SSRIs during the study period, respectively, whereas among the controls, the corresponding numbers were 22.3 and 6.8%. Generally, the frequency of drug prescriptions for cases was higher than that of the controls. Table 2 shows the RR estimates for the effect of over use of antidepressants on the incidence of prostate cancer for subjects with different lengths of histories before index date. Ever being exposed to TCAs was significantly associated with the incidence of prostate cancer, with adjusted RRs ranging from 1.88 (95% CI 1.48-2.40) for those having 2-5 years of history to 1.19 (95% CI 1.04-1.35) for those having 16-20 years of history. Similarly, exposure to SSRIs in the 2-10 years before the index date was associated with the incidence of prostate cancer, adjusted RR ¼ 1.26 (95% CI 1.01-1.57).
The RR estimates of the association between cumulative dosage of antidepressants and prostate cancer incidence, among the same groups of subjects, are summarized in Table 3 . Incidence of prostate cancer was significantly associated with higher cumulative dosage of exposure to TCAs among those having 2-5, 6-10 and 11-15 years of history before the index date (P-trends were 0.0001, 0.02 and 0.05, respectively). For SSRIs, the adjusted RR at the high dosage level was statistically significant (adjusted RR ¼ 1.66, 95% CI 1.18-2.32). But there was no evidence of statistically significant trend in the association (P-trend ¼ 0.1). Table 4 shows that the only period in which exposure to TCAs had a statistically significant association with the incidence of prostate cancer was the 2-5 year period before the index date (P-trend ¼ 0.0001). In this period, the adjusted RRs increased from 1.31 (95% CI 1.14-1.51) at the lower tercile to 2.42 (95% CI 1.87-3.12) at the higher tercile of the average daily dose of TCAs. Although the RR for the medium level of average daily dose of exposure to SSRIs in the period 2-5 year was found to be significantly associated with the incidence of prostate cancer (adjusted RR ¼ 1.82; 95% CI 1.20-2.75), the P-trend for this association was not significant (P-trend ¼ 0.25).
Finally, the results for the association between the duration of exposure to TCAs and SSRIs and the incidence of prostate cancer (Table 5) were similar to those found in the average daily dose analyses. The adjusted RRs for the incidence of prostate cancer in association with exposure to TCAs in the 2-5 years period before the index date increased from 1.26 (95% CI 1.08-1.47) for short duration of use to 2.31 (95% CI 1.78-2.99) for the longest duration (P-trend ¼ 0.0001). Moreover, exposure to medium duration of SSRIs in the 2-5 year period was associated with an adjusted RR of 1.46 (95% CI 1.03-2.07) but the P-trend was not statistically significant (0.6).
Discussion
In the present study, we used two different approaches to analyze the effect of antidepressant use on the risk of Abbreviations: CI, confidence interval; RR, rate (incidence) ratio; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
a Adjustment for exposure to other drugs, as well as the number of prescriptions in the 5 years before index date. P-trend was based on the continuous data rather than the categorical data.
Antidepressants and risk of prostate cancer HM Tamim et al developing prostate cancer. The first set of analyses, which were stratified by length of exposure history, revealed a 90% increase in risk of prostate cancer among users of TCAs who had between 2 and 5 years of history. This association became progressively weaker with longer duration of history. One explanation for this pattern is that our use of cumulative exposure measures spanning the entire history may have diluted the estimated effects because such measures combine periods of both etiologically relevant and irrelevant exposures. 19 Because the exact time period during which the most relevant exposure occurs is not known, we examined the effect of TCA use on prostate cancer risk within four a priori determined periods before the index date. These analyses showed that the positive associations were limited to the period of 2-5 years before diagnosis with a tendency for stronger associations with longer duration of use and higher average daily dose. A similar pattern of results was found for SSRI use, though information on long-term use of SSRI was not available because of their more recent introduction into the market.
This study had several methodological strengths including a design, which reduced the potential for recall bias in terms of exposure to antidepressants because pre-recorded exposure histories were used. Also use of population-based data limited the potential for selection bias. The study included all cases of prostate cancer identified by the Saskatchewan Cancer Agency registry, a population-based cancer registry known for its high levels of registration completeness and pathological confirmation 20, 21 and a random sample of controls from the same source population. The very large sample size provided reasonably precise estimates for the effects of antidepressant use and permitted the examination of the effect of timing of use.
There are also several limitations of the present study. One limitation was the fact that data on drug prescription for all subjects (cases and controls)-between 1 July 1987 and 31 December 1988-were not provided because Abbreviations: CI, confidence interval; RR, rate (incidence) ratio; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants. Other: subjects with incomplete information during the specified period.
a Adjustment for exposure to the medication of interest in the other periods, as well as exposure to other drugs and the number of prescriptions in the 5 years before index date. P-trend was based on the continuous data rather than the categorical data.
Antidepressants and risk of prostate cancer HM Tamim et al capture of prescription information was incomplete during this period. As a consequence, we considered all the cases and controls to be unexposed during this one and a half year period. Such an exposure misclassification is thought to be non-differential (not related to case -control status) and is, therefore, expected to bias measures of association towards the null value (as shown by the results of sensitivity analyses done, results not shown). We also did not have information on antidepressants dispensed during hospitalizations or as samples in physicians' offices; nevertheless, these amounts were probably small relative to the amounts used in calculating exposure. Moreover, patients who receive antidepressants in hospitals or as samples in physicians' offices are very likely to continue treatment, and thus be identified as 'exposed'. Finally, the exposure definition used in this study did not refer to actual consumption of antidepressants, but rather to the dispensed antidepressant prescriptions. As a consequence, overestimation of exposure may have occurred, because it is unlikely that all drugs dispensed were ingested. The slope of the dose -risk relationship that we observed would then be expected to be less than the true slope. 22 The possibility of confounding by other risk factors for prostate cancer should also be considered. We matched on age and adjusted for use of other medications that may influence the risk of prostate cancer such as NSAIDs 23 and drugs used in the treatment of hypertension and heart disease. 24 Nevertheless, we did not have information on family history of prostate cancer and ethnicity and thus we could not control for these variables. However, family history of prostate cancer is unlikely to be a confounder, because there is no reason to believe that it would be associated with antidepressant use. Confounding by ethnicity is also unlikely because the population of older men in Saskatchewan is fairly homogeneous. We did not have information on other putative risk factors for prostate cancer that may be related to depression or antidepressant use such as smoking, alcohol consumption and physical activity. In previous pharmacoepidemiologic studies of prostate cancer that adjusted for these factors, the multivariate-adjusted Abbreviations: CI, confidence interval; RR, rate (incidence) ratio; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants. Other: subjects with incomplete information during the specified period.
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Like most of the epidemiologic literature on prostate cancer, we were not able to verify whether the controls were free of undiagnosed cancer. Occult foci of prostate cancer are relatively common among older men. Assuming that both clinically detected cases and unsuspected cases share similar etiology, the inclusion of unsuspected cases in the control group may mask some associations. 26 Moreover, we did sensitivity analyses, where we excluded the controls who were diagnosed with prostate cancer in the following 5 years (since they will be identified as cases at a later point in our study), and the results were not affected.
Our findings of a positive association with TCA use that was limited to the 5-year period before diagnosis do not support an etiological role for TCAs in initiating prostate carcinogenesis since prostate cancer tends to be slow-growing with protracted latency period; up to 2-3 decades are required before the disease appears clinically. 27 However, the possibility that TCA use may promote the growth or progression of pre-existing tumors cannot be ruled out, though that proposition too seems unlikely because even progression from the most aggressive high-grade prostate intraepithelial neoplasia to a focal carcinoma may take 2-3 years. 28 An alternative and perhaps more likely explanation is increased likelihood of prostate cancer detection among antidepressant users compared to non-users. This would be the case if depressed patients receiving antidepressants on regular basis are more likely to be screened for prostate cancer because of more frequent contact with health care providers or because depressed patients sometimes present with somatic complaints that could trigger prostate cancer screening. In addition, antidepressants are sometimes prescribed for the treatment of prostodynia and chronic non-inflammatory abacterial prostatitis. 29 Men suffering from these conditions are also more likely to be screened for prostate cancer. Detection bias could also explain the duration -response effect of TCA use if longer duration of use increases the chances for prostate cancer screening and detection, but it does not explain the dose -response effect unless one postulates that patients who receive high doses of TCAs are also likely to be treated for longer period of time.
Another plausible explanation is confounding by indication which may occur if drug use is just a marker of a disease or condition that increases prostate cancer risk. 30 It has been hypothesized that depression could be associated with the development of cancer as the result of immunologic and endocrine dysfunction, 31 but there is little evidence to substantiate this theory. Dalton et al. 32 have recently reviewed the epidemiologic evidence for an association between depression and cancer. Most reviewed studies found either a slight increase in risk, mostly in relation to breast cancer and smoking-related cancers, or no association at all. They concluded that because of the weak and inconsistent associations, the lack of well-defined plausible biological mechanisms, and the possibility of confounding by social and behavioral factors such as smoking and alcohol consumption, a causal relation between depression and cancer is not very likely. This conclusion was recently supported by the findings of a large population-based study which found no association between hospitalization with affective disorders and risk of cancer. 33 The standardized incidence ratio for prostate cancer in this study was 0.96 (95% CI 0.83-1.11) for patients with bipolar and unipolar affective disorders and 1.02 (95% CI 0.84-1.23) for patients with reactive depression and dysthymia.
Protopathic bias (reverse causality) could have also affected our results. The slow-growing nature of prostate cancer could have rendered our attempt to control for this type of bias (by excluding exposure in the year before the index date) to be inadequate. Finally, random effect could be another explanation especially that this project is part of a larger study conducted to assess the association between antidepressants and the risk of 17 different cancers.
The association between TCA use and the risk of cancer was assessed in different epidemiologic studies, most of which did not find any positive association, 7, 8, [34] [35] [36] though few reported a positive association. 6, 10, [37] [38] [39] Two studies had information on prostate cancer and they both implied that there was no statistically significant association with use of TCA or SSRIs. 40 So far, laboratory and experimental studies of the role of antidepressants in cancer development have produced conflicting results. Recently, Sternback reviewed 13 studies that used human tumor cell line and animal models to examine the effects of TCAs and SSRIs on carcinogenesis. He reported that six such studies found no increase in risk whereas seven found a significant increase or trend towards increase in risk. 41 In one study, Abdul et al. reported that three SSRIs, including fluoxetine, inhibited the in vitro growth of three prostate cancer cell lines. Fluoxetine also significantly inhibited the growth of prostate cancer xenografts in athymic nude mice. 42 Because all three SSRIs blocked the uptake of a radiolabeled analog of serotonin by prostate cancer cells, Abdul et al. postulated that serotonin may stimulate cell division and cancer growth. If that is true, SSRI may actually decrease the risk of prostate cancer but we did not see evidence for such an effect in the present study. Our study was, however, limited by lack of information on long-term use of SSRIs.
In conclusion, we found that TCA use was associated with a small dose-dependent increase in risk of prostate cancer detection that was limited to the period of 2-5 years before diagnosis. However, an etiological role seems unlikely in light of the short latency period of this effect and the high likelihood of detection bias. While the results of this study do not provide support for the hypothesis that TCA or SSRI use increases the prostate cancer risk, further studies with adequate exposure measurements and careful control for detection bias are needed.
